XSpray Pharma Valuation
| XSPRAY Stock | SEK 41.40 1.10 2.59% |
At this time, the company appears to be overvalued. XSpray Pharma AB maintains a prevalent Real Value of kr39.07 per share. The last-minute price of the company is kr41.4. Our model calculates the value of XSpray Pharma AB from examining the company fundamentals such as Operating Margin of (116.51) %, return on asset of -0.14, and Shares Outstanding of 22.68 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that XSpray Pharma's price fluctuation is very steady at this time. Calculation of the real value of XSpray Pharma AB is based on 3 months time horizon. Increasing XSpray Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since XSpray Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XSpray Stock. However, XSpray Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 41.4 | Real 39.07 | Hype 41.4 | Naive 49.79 |
The real value of XSpray Stock, also known as its intrinsic value, is the underlying worth of XSpray Pharma AB Company, which is reflected in its stock price. It is based on XSpray Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of XSpray Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of XSpray Pharma AB helps investors to forecast how XSpray stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XSpray Pharma more accurately as focusing exclusively on XSpray Pharma's fundamentals will not take into account other important factors: XSpray Pharma Total Value Analysis
XSpray Pharma AB is at this time projected to have takeover price of 1.16 B with market capitalization of 1.45 B, debt of 1.19 M, and cash on hands of 192.85 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the XSpray Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.16 B | 1.45 B | 1.19 M | 192.85 M |
XSpray Pharma Asset Utilization
One of the ways to look at asset utilization of XSpray is to check how much profit was generated for every dollar of assets it reports. XSpray Pharma AB maintains a negative usage of resources of -0.14 (%), losing kr0.001448 for each kronor of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each kronor of resources it maintains. Specifically, asset utilization of XSpray Pharma AB shows how discouraging it operates for each kronor spent on its resources.XSpray Pharma Ownership Allocation
XSpray Pharma AB retains a total of 22.68 Million outstanding shares. XSpray Pharma AB owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.XSpray Pharma Profitability Analysis
Net Loss for the year was (96.7 M) with profit before overhead, payroll, taxes, and interest of 656 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates XSpray Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in XSpray Pharma and how it compares across the competition.
About XSpray Pharma Valuation
The stock valuation mechanism determines XSpray Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of XSpray Pharma. We calculate exposure to XSpray Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XSpray Pharma's related companies.Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct XSpray Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates XSpray Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct XSpray Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain XSpray Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine XSpray Pharma's revenue streams: Identify XSpray Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research XSpray Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish XSpray Pharma's growth potential: Evaluate XSpray Pharma's management, business model, and growth potential.
- Determine XSpray Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate XSpray Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for XSpray Stock analysis
When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |